1.The Third Nationwide Korean Heart Failure III Registry (KorHF III):The Study Design Paper
Minjae YOON ; Eung Ju KIM ; Seong Woo HAN ; Seong-Mi PARK ; In-Cheol KIM ; Myeong-Chan CHO ; Hyo-Suk AHN ; Mi-Seung SHIN ; Seok Jae HWANG ; Jin-Ok JEONG ; Dong Heon YANG ; Jae-Joong KIM ; Jin Oh CHOI ; Hyun-Jai CHO ; Byung-Su YOO ; Seok-Min KANG ; Dong-Ju CHOI
International Journal of Heart Failure 2024;6(2):70-75
With advancements in both pharmacologic and non-pharmacologic treatments, significant changes have occurred in heart failure (HF) management. The previous Korean HF registries, namely the Korea Heart Failure Registry (KorHF-registry) and Korean Acute Heart Failure Registry (KorAHF-registry), no longer accurately reflect contemporary acute heart failure (AHF) patients. Our objective is to assess contemporary AHF patients through a nationwide registry encompassing various aspects, such as clinical characteristics, management approaches, hospital course, and long-term outcomes of individuals hospitalized for AHF in Korea. This prospective observational multicenter cohort study (KorHF III) is organized by the Korean Society of Heart Failure. We aim to prospectively enroll 7,000 or more patients hospitalized for AHF at 47 tertiary hospitals in Korea starting from March 2018. Eligible patients exhibit signs and symptoms of HF and demonstrate either lung congestion or objective evidence of structural or functional cardiac abnormalities in echocardiography, or isolated right-sided HF. Patients will be followed up for up to 5 years after enrollment in the registry to evaluate long-term clinical outcomes. KorHF III represents the nationwide AHF registry that will elucidate the clinical characteristics, management strategies, and outcomes of contemporary AHF patients in Korea.
2.Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
Chang Wook JEONG ; Jang Hee HAN ; Dong Deuk KWON ; Jae Young JOUNG ; Choung-Soo KIM ; Hanjong AHN ; Jun Hyuk HONG ; Tae-Hwan KIM ; Byung Ha CHUNG ; Seong Soo JEON ; Minyong KANG ; Sung Kyu HONG ; Tae Young JUNG ; Sung Woo PARK ; Seok Joong YUN ; Ji Yeol LEE ; Seung Hwan LEE ; Seok Ho KANG ; Cheol KWAK
Cancer Research and Treatment 2024;56(2):634-641
Purpose:
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods:
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results:
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.
3.The Role of Measuring Preoperative Social Maturation Score in Children With Additional Needs Who Underwent Cochlear Implantation
Ji Won CHOI ; Yun Ji LEE ; Woo Seok KANG ; Joong Ho AHN ; Hong Ju PARK ; Jong Woo CHUNG
Journal of Audiology & Otology 2024;28(2):107-113
Background and Objectives:
Additional needs refer to specific requirements or support for individuals with disabilities or syndromes. Intellectual ability is a crucial outcome determinant of a cochlear implant. The social quotient (SQ) is an indirect predictor of intellectual capacity and social skills. This study aimed to investigate the clinical significance of the SQ on children with additional needs who received cochlear implants. Subjects and
Methods:
This study included 24 patients with diagnosed developmental delays and syndromes, who demonstrated SQ scores of <70. Preoperative social skills were evaluated using the SQ. All patients underwent cochlear implantation (CI) surgery before 7 years of age. Outcomes were evaluated using the Infant-Toddler Meaningful Auditory Integration Scale (IT-MAIS) and Categories of Auditory Performance (CAP) scores. Data were collected through a retrospective chart review.
Results:
Children were categorized into three groups based on their SQ. There were no correlations between the preoperative SQ and IT-MAIS or CAP scores at 2 and 5 years of follow-up postoperatively. The CI outcomes of children with low SQ (<70) differed from those with normal development (SQ>70). In the low-SQ group, inner ear anomalies were observed in 10 (41.7%) patients. Although not statistically significant, these children exhibited a trend of lower average outcomes than children without inner ear anomalies.
Conclusions
CI outcomes in children with additional needs positively affected auditory performance. Postoperative auditory and language skills tended to improve slowly in children with additional needs and a lower SQ. Over time, development gradually became more comparable to the other groups of children. However, this improvement was less than that observed in children without additional needs. Our findings support CI for children with additional needs as part of long-term auditory rehabilitation following surgery.
4.Status of the Newborn Hearing Screening in the 4-Months Age National Infant Health Checkup in Korea: A Nationwide PopulationBased Study
Jiwon CHANG ; Su-Kyoung PARK ; Gi Jung IM ; Joong Ho AHN ; Jun Ho LEE ; Kyungdo HAN ; Jong Woo CHUNG ; Jin-Sook KIM ; Hyunsook JANG ; Seung Hwan LEE
Journal of Korean Medical Science 2023;38(4):e29-
Background:
The aims of this study are to review data on 4-months age National Health Screening Program for Infants and Children (NHSPIC) using a National Health Insurance Service (NHIS) database, and to analyze the newborn hearing screening (NHS) results and related characteristics of the 4-months NHSPIC for 7 years in South Korea.
Methods:
We analyzed a NHIS database of infants who had participated in the 4-month age NHSPIC from 2010 to 2016. According to the results of hearing questionnaires and physical examination, we analyzed the outcomes of NHS and related infantile and socioeconomic factors.
Results:
Among 3,128,924 of total eligible infants in Korea between the year 2010 and 2016, 69.2% (2,164,621 infants) conducted 4-months age NHSPIC, and 94.4% (2,042,577 infants) of which performed hearing questionnaires regarding NHS. Among the total hearing examinees, premature infants accounted for 3.6%, infants who were hospitalized in the neonatal intensive care unit (NICU) for more than 5 days accounted for 5.6%, and infants with head and neck abnormalities were 0.6%. The NHS performing rate was 79.1% for total hearing examinees in 2010, but gradually increased to 88.9% in 2016. The NHS performing rate in 2016 was 93.4% for premature infants, 91.7% for NICU hospitalized babies. The mean referral rate was 0.6% for total hearing examinees, 1.4% for premature infants, and 2.3% for NICU hospitalized babies. When we analyzed the NHS performing rate and the referral rate according to the household income level, the NHS performing rate of infants in Medical Aid programs was the lowest as 65.6%, and the NHS performing rates in other five levels of NHIS was higher ranging between 85.1% to 86.0%. The referral rate of infants in the Medical Aid program (3.8%) was significantly higher than those of infants in other classes (1.10–1.25%).
Conclusion
The estimated overall NHS performing rate in Korea gradually increased and was 88.9% in 2016. The overall referral rate was low as 0.6%, and it was significantly different depending on the infant’s health condition and household income levels. We assume that our finding would help to establish policies managing hearing impaired children, and to develop the customized hearing care service programs considering the household economic levels.
5.Korean guidelines for the management of gout
Jennifer Jooha LEE ; Ji Soo LEE ; Min Kyung CHUNG ; Joong Kyong AHN ; Hyo-Jin CHOI ; Seung-Jae HONG ; Chong-Hyeon YOON ; Su-Hyun KIM ; Kyung-Hwan JEONG ; Jong-Woo KIM ; Bo-Yeon KIM ; Jin-Ho SHIN ; Woo Gyu KIM ; Soo-Young KIM ; Hyun-Jung KIM ; Jeong-Soo SONG ; Jae-Bum JUN ; Hyun-Ah PARK ; Shung Chull CHAE ; Bum Soon CHOI ; Tae Nyun KIM ; Hyun Ah KIM
Journal of Rheumatic Diseases 2023;30(3):141-150
Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical period, and prevention of chronic complications. The guidelines were developed based on evidence-based medicine and draft recommendations finalized after expert consensus. These guidelines are designed to provide clinicians with clinical evidence to enable efficient treatment of gout.
6.Korean guidelines for the management of gout
Jennifer Jooha LEE ; Ji Soo LEE ; Min Kyung CHUNG ; Joong Kyong AHN ; Hyo-Jin CHOI ; Seung-Jae HONG ; Chong-Hyeon YOON ; Su-Hyun KIM ; Kyung-Hwan JEONG ; Jong-Woo KIM ; Bo-Yeon KIM ; Jin-Ho SHIN ; Woo Gyu KIM ; Soo-Young KIM ; Hyun-Jung KIM ; Jeong-Soo SONG ; Jae-Bum JUN ; Hyun-Ah PARK ; Shung Chull CHAE ; Bum Soon CHOI ; Tae Nyun KIM ; Hyun Ah KIM
The Korean Journal of Internal Medicine 2023;38(5):641-650
Gout is the most common form of arthritis, with the prevalence increasing worldwide. The present treatment guidelines provide recommendations for the appropriate treatment of acute gout, management during the inter-critical period, and prevention of chronic complications. The guidelines were developed based on evidence-based medicine and draft recommendations finalized after expert consensus. These guidelines are designed to provide clinicians with clinical evidence to enable efficient treatment of gout.
7.A Comparison of Endolymphatic Sac Decompression and Intratympanic Gentamicin for Treatment of Meniere’s Disease
Hye Ah JOO ; In Seong JEONG ; Woo Seok KANG ; Hong Ju PARK ; Jong Woo CHUNG ; Joong Ho AHN
Korean Journal of Otolaryngology - Head and Neck Surgery 2022;65(11):669-677
Background and Objectives:
Meniere’s disease (MD) is primarily managed by lifestyle and dietary changes. There are several non-medical treatment options for medically intractable MD; however, treatment results still remain controversial. This study aims to review the treatment outcome of endolymphatic sac decompression (ESD) and intratympanic gentamicin (ITG) for MD refractory to medical management.Subjects and Method The medical records of 50 patients, diagnosed with definite MD intractable to medical management, who underwent ESD or ITG from 2010 to 2020 at a tertiary referral hospital, were retrospectively reviewed. ESD was first considered in patients with serviceable hearing (pure tone audiometry average value less than 50 dB, speech discrimination score of 50% or greater). One-year post-treatment audiological changes and vertigo control were reviewed and compared between the two groups.
Results:
Fifty patients (ears) were enrolled in this study (ESD, n=27; ITG, n=23). There was a post-treatment hearing gain (2.3 dB HL) in the ESD group (p=0.509), while there was an overall post-treatment hearing decline (2.2 dB HL) in the ITG group (p=0.178), with no significant difference between two groups regarding hearing change (p=0.212). Regarding vertigo control, 66.6% and 56.5% patients in the ESD and ITG groups, respectively, were classified as vertigo class A or B, with statistically significant difference between both groups (p=0.027).
Conclusion
ESD conferred better post-treatment vertigo control than ITG, but there were no significant hearing changes in both groups. ESD is an effective treatment for patients with medically intractable MD who has serviceable hearing.
8.Determinants of Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
Ji-won HWANG ; Sang-Chol LEE ; Darae KIM ; Jihoon KIM ; Eun Kyoung KIM ; Sung-A CHANG ; Sung-Ji PARK ; Sung Mok KIM ; Yeon Hyeon CHOE ; Joong Hyun AHN ; Seung Woo PARK
Journal of Korean Medical Science 2022;37(8):e62-
Background:
Reduced exercise capacity reflects symptom severity and clinical outcomes in patients with hypertrophic cardiomyopathy (HCM). The present study aimed to identify factors that may affect exercise capacity in patients with HCM.
Methods:
In 294 patients with HCM and preserved left ventricular (LV) ejection fraction, we compared peak oxygen consumption (peak VO2 ) evaluated by cardiopulmonary exercise testing as a representative parameter of exercise tolerance with clinical and laboratory data, including N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP), diastolic parameters on echocardiography, and the grade of myocardial fibrosis on cardiac magnetic resonance imaging (CMR).
Results:
Median peak VO2 , was 29.0 mL/kg/min (interquartile range [IQR], 25.0–34.0). Age (estimated β = −0.140, P < 0.001), female sex (β = −5.362, P < 0.001), NT-proBNP (β = −1.256, P < 0.001), and E/e′ ratio on echocardiography (β = −0.209, P = 0.019) were significantly associated with exercise capacity. Peak VO2 was not associated with the amount of myocardial fibrosis on CMR (mean of late gadolinium enhancement 12.25 ± 9.67%LV).
Conclusion
Decreased exercise capacity was associated with age, female sex, increased NTproBNP level, and E/e′ ratio on echocardiography. Hemodynamic changes and increased filling pressure on echocardiography should be monitored in this population for improved outcomes.
9.Diagnostic Validity of Auditory Brainstem Response for the Initial Screening of Vestibular Schwannoma
Marn Joon PARK ; Joong Ho AHN ; Hong Ju PARK ; Jong Woo CHUNG ; Woo Seok KANG
Journal of Audiology & Otology 2022;26(1):36-42
Background and Objectives:
To investigate the diagnostic validity of auditory brainstem response (ABR) in the screening of vestibular schwannoma (VS).
Subjects and Methods:
Forty patients diagnosed with VS using magnetic resonance imaging who had undergone ABR before treatment between 2005 and 2015 were included. ABR results were considered positive when findings met at least one of the following criteria: 1) absent evoked response, 2) desynchronization of waves other than wave I, 3) interpeak latency (IPL) between waves I and III >2.5 ms, 4) IPL between waves I and V >4.4 ms, 5) wave V interaural latency difference >0.2 ms, and 6) interaural difference in IPL between waves I and V >0.2 ms.
Results:
The overall sensitivity of ABR was 85.0%. For tumors measuring <10 mm, the sensitivity of ABR was 66.7%, whereas it increased to 90.3% for tumors measuring >10 mm. The sensitivity of tumors confined to the internal acoustic canal was 73.3% compared with 100.0% for tumors confined to the cerebellopontine angle. In patients with serviceable hearing, the mean tumor size was 7.8±2.9 mm in patients with a normal ABR and 15.1±9.4 mm in patients with an abnormal ABR, indicating a significant difference (p<0.05).
Conclusions
ABR alone is insufficient for the screening of VS, bearing the risk of false-negative outcomes when examining small, intracanalicular tumors. However, ABR can be inexpensively applied for the screening of VS measuring >10 mm in patients with serviceable hearing, supporting the need for further active diagnostic and treatment modalities in clinical practice.
10.Increased Healthcare Delays in Tuberculosis Patients During the First Wave of COVID-19 Pandemic in Korea: A Nationwide Cross-Sectional Study
Jinsoo MIN ; Yousang KO ; Hyung Woo KIM ; Hyeon-Kyoung KOO ; Jee Youn OH ; Yun-Jeong JEONG ; Hyeon Hui KANG ; Kwang Joo PARK ; Yong Il HWANG ; Jin Woo KIM ; Joong Hyun AHN ; Yangjin JEGAL ; Ji Young KANG ; Sung-Soon LEE ; Jae Seuk PARK ; Ju Sang KIM
Journal of Korean Medical Science 2022;37(3):e20-
Background:
The coronavirus disease 2019 (COVID-19) pandemic caused disruptions to healthcare systems, consequently endangering tuberculosis (TB) control. We investigated delays in TB treatment among notified patients during the first wave of the COVID-19 pandemic in Korea.
Methods:
We systemically collected and analyzed data from the Korea TB cohort database from January to May 2020. Groups were categorized as ‘before-pandemic’ and ‘during-pandemic’ based on TB notification period. Presentation delay was defined as the period between initial onset of symptoms and the first hospital visit, and healthcare delay as the period between the first hospital visit and anti-TB treatment initiation. A multivariate logistic regression analysis was performed to evaluate factors associated with delays in TB treatment.
Results:
Proportion of presentation delay > 14 days was not significantly different between two groups (48.3% vs. 43.7%, P = 0.067); however, proportion of healthcare delay > 5 days was significantly higher in the during-pandemic group (48.6% vs. 42.3%, P = 0.012). In multivariate analysis, the during-pandemic group was significantly associated with healthcare delay > 5 days (adjusted odds ratio = 0.884, 95% confidence interval = 0.715–1.094).
Conclusion
The COVID-19 pandemic was associated with healthcare delay of > 5 days in Korea. Public health interventions are necessary to minimize the pandemic’s impact on the national TB control project.

Result Analysis
Print
Save
E-mail